Observational studyCardiovascular diabetology2020
Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus.
Observational study in Cardiovascular diabetology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- The High-Sensitivity C-Reactive Protein-Albumin-Lymphocyte Index Is a Prognostic Marker for All-Cause and Cardiovascular Mortality in Patients With ST-Elevation Myocardial Infarction.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
- Admission BNP-dominant biomarker phenotypes and in-hospital heart failure or cardiogenic shock in STEMI: a retrospective research note.BMC research notes · 2026Article
- Association of the inflammatory burden index with 1-year major adverse cardiovascular events in patients with HFpEF after myocardial infarction: a single-center retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- AI approaches for predicting progression to acute coronary syndrome among stable coronary heart disease patients.NPJ cardiovascular health · 2025Article
- Prognostic value of the C-reactive protein-to-albumin ratio in acute decompensated heart failure across different glucose metabolism statuses.Scientific reports · 2025Article
- Association Between Serum Lipid-Bilirubin Ratio and Clinical Prognosis Among Patients Undergoing Percutaneous Coronary Intervention After Coronary Artery Bypass Grafting.Reviews in cardiovascular medicine · 2025Article
- Article
- Inflammatory markers guide early risk stratification and prognosis in elderly patients with acute myocardial infarction.Scientific reports · 2025Article
- Hypoglycemia and glycemic variability in acute myocardial infarction: the lesser-known aspects of glycemic control.Cardiovascular diabetology · 2025Review
- Hs-CRP, Diabetic Status, and Adverse Events Among Patients Receiving Statin Therapy Following PCI-A Prospective Registry-Based Study.Journal of inflammation research · 2025Article
- Development and validation of a machine learning-based readmission risk prediction model for non-ST elevation myocardial infarction patients after percutaneous coronary intervention.Scientific reports · 2024Article
- Article
- Predictive Value of the Modified GRACE Scoring System for All-Cause Mortality in Patients with Acute Myocardial Infarction.Reviews in cardiovascular medicine · 2023Article
- The Impact of Systemic Inflammation Response Index on the Prognosis of Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.Reviews in cardiovascular medicine · 2023Article
- Predictive value of high sensitivity C-reactive protein in three-vessel disease patients with and without type 2 diabetes.Cardiovascular diabetology · 2023Article
- Association of physiological stress markers at the emergency department to readmission and death within 90 days: a prospective observational study.Upsala journal of medical sciences · 2023Observational
- Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction.Journal of clinical medicine · 2022Article
- Cardiogenic Shock Does Not Portend Poor Long-Term Survival in Patients Undergoing Primary Percutaneous Coronary Intervention.Journal of personalized medicine · 2022Article
- Admission high-sensitivity C-reactive protein levels improve the Grace risk score prediction on in-hospital outcomes in acute myocardial infarction patients.Clinical cardiology · 2022Article
- Cardiac biomarkers and detection methods for myocardial infarction.Molecular & cellular toxicology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-sensitivity C-reactive protein (hs-CRP) elevation frequently occurs in acute myocardial infarction (AMI) and is associated with adverse outcomes. Since diabetes mellitus (DM) is characterized by an underlying chronic inflammation, hs-CRP may have a different prognostic power in AMI patients with and without DM.
methodsWe prospectively included 2064 AMI patients; hs-CRP was measured at hospital admission. Patients were grouped according to hs-CRP quartiles and DM status. The primary endpoint was a composite of in-hospital mortality, cardiogenic shock, and acute pulmonary edema. Two-year all-cause mortality was the secondary endpoint.
resultsTwenty-six percent (n = 548) of patients had DM and they had higher hs-CRP levels than non-DM patients (5.32 vs. 3.24 mg/L; P < 0.0001). The primary endpoint incidence in the overall population (7%, 9%, 13%, 22%; P for trend < 0.0001), in DM (14%, 9%, 21%, 27%; P = 0.0001), and non-DM (5%, 8%, 10%, 19%; P < 0.0001) patients increased in parallel with hs-CRP quartiles. The adjusted risk of the primary endpoint increased in parallel with hs-CRP quartiles in DM and non-DM patients but this relationship was less evident in DM patients. In the overall population, the adjusted OR of the primary endpoint associated with an hs-CRP value ≥ 2 mg/L was 2.10 (95% CI 1.46-3.00). For the same risk, hs-CRP was 7 and 2 mg/L in patients with and without DM. A similar behavior was observed for the secondary endpoint when the HR associated with an hs-CRP value ≥ 2 mg/L found in the overall population was 2.25 (95% CI 1.57-3.22). For the same risk, hs-CRP was 8 and 1.5 mg/L in DM and non-DM patients.
conclusionsThis study shows that hs-CRP predicts in-hospital outcome and two-year mortality in AMI patients with and without DM. However, in DM patients, the same risk of developing events as in non-DM patients is associated to higher hs-CRP levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.